Could a gentler chemo combo with delayed immunotherapy tame advanced lung cancer?
NCT ID NCT07647094
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates whether a lower dose of two chemotherapy drugs (carboplatin and nab-paclitaxel) combined with a delayed dose of the immunotherapy serplulimab can effectively treat advanced squamous non-small cell lung cancer. The trial compares this gentler regimen to a standard-dose version in about 112 adults with advanced or metastatic disease. The goal is to see if the lower-dose approach can control the cancer while reducing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Serplulimab, Nab-Paclitaxel, Carboplatin
What this could lead to
If successful, this could offer a less toxic first-line treatment option for advanced squamous lung cancer, potentially improving quality of life while controlling the disease.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not be conclusive. Lower doses might reduce side effects but could also be less effective at controlling the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Quzhou people's Hospital
RECRUITINGQuzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••